Doxorubicin is a widely used chemotherapy drug. It can also damage the heart, which limits how much of it patients can safely receive. Researchers writing in Cardiovascular Toxicology asked a focused question: in laboratory studies, do incretin-based drugs such as GLP-1 receptor agonists and dual GIP/GLP-1 agonists show any protective effect against this kind of heart injury?
This was a systematic review, meaning the authors gathered and summarized existing studies rather than running a new experiment. Every eligible study was in animals. Thirteen rodent studies qualified, and the researchers found no human study that met their criteria. That detail matters for anyone reading this as if it applies to people. It does not, at least not yet.
What the researchers actually did
The team followed PRISMA 2020 reporting standards, a common framework for transparent reviews. They searched four large databases, PubMed/MEDLINE, Embase, Web of Science, and Scopus, through 20 October 2025. They limited eligibility to rodent models of doxorubicin heart injury plus any clinical study directly testing these drugs during doxorubicin exposure.
They excluded cell-only studies, models that did not use doxorubicin, combination-treatment studies, gene therapy approaches, and reviews or editorials. To judge study quality, they used the SYRCLE risk-of-bias tool and a version of GRADE adapted for preclinical work.
What the studies reported
The drugs examined were liraglutide in four studies, exenatide or exendin-4 in four, semaglutide in two, and tirzepatide in three. In models using repeated cumulative doses of doxorubicin, the incretin drugs were generally associated with preserved left ventricular systolic function. Across studies, ejection fraction differences ran roughly 7 to 20 percentage points, alongside lower levels of heart injury biomarkers.
The authors also noted reductions in oxidative stress, inflammation, and apoptosis, and in some studies a form of cell death called ferroptosis. In acute single-dose models, results were less consistent. The clearest protective signal appeared when the incretin drug was given at the same time as doxorubicin. Pretreatment alone with liraglutide or tirzepatide, and post-treatment with exenatide, did not show a clear added benefit.
What this does not mean
These are animal findings. The review did not identify a single human study, so nothing here tells us whether these drugs protect the heart in people receiving chemotherapy. A percentage-point change in a mouse heart measurement is not a treatment claim for patients. The authors are explicit that the results are hypothesis-generating and should wait for carefully designed clinical trials before anyone draws conclusions about human care.
It is also worth being precise about status. GLP-1 and dual agonist peptides are prescription drugs in some approved uses and investigational in others. Using any of them to prevent chemotherapy heart injury is not an established or approved use. This article is educational and not medical advice.
One honest limitation
The authors flag their own biggest weakness. The evidence rests entirely on small, heterogeneous animal studies that used mostly male animals and varied widely in dose and timing. Using the adapted GRADE approach, they rated the certainty of the evidence as low to very low. That is a candid signal that the findings are early and fragile, not a foundation for changing anything a person does.
If you are undergoing cancer treatment and worried about heart effects, that is a conversation for your oncologist and cardiologist. A licensed clinician can weigh your situation against real clinical evidence, which this review did not find for humans.